Topical Hemostatic Agents Patents: Top Companies & Trends 2026
- 41.1% concentration. The top 5 assignees hold 2,680 of 6,517 records in scope — a field where a handful of surgical and biopharma names have staked most of the claim space.
- Filing has cooled from a 2017 peak. 293 records published in 2017 versus 12 so far in the partial most-recent year, with a -52% drop from 2021 (220) to 2024 (105) — the last year the trend can be read as complete.
- A61K and A61L each cover roughly 40% of records. Medicinal preparations and sterilising/disinfecting classes dominate, while polymer composition claims (C08L, 4.8%) remain comparatively open.
Filing growth compares 2021 (220 records) with 2024 (105) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 6,517 records in scope (CR5), not by the ranked leaders only.
What the topical hemostatic agent patent record shows
Topical hemostatic agents sit at the intersection of surgical device engineering and biomaterials chemistry — oxidized cellulose scaffolds, gelatin matrices, and powders formulated for fast clotting time and controlled absorption profile. The 6,517 records in scope span 2015 through mid-2026, drawing on a search string built around clotting performance and handling-property claims rather than a single chemistry. Filing concentrated heavily around a 2017 peak and has since declined through the years that can be read as complete, though publication lag means the very latest years always understate true filing activity.
Assignee concentration is pronounced: the leading company alone accounts for 858 records, and the top 5 combine for 41.1% of all records in scope. That leaves a long tail of smaller filers working narrower formulation or delivery-device niches, which is where openings for new entrants tend to persist.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 6,517-record dataset: how filing volume has moved year over year, and how records distribute across IPC subclasses. Because a single record can carry several IPC codes, the class shares below sum to well over 100% of the record total — that overlap is expected and reflects how broadly hemostatic-agent claims typically reach across chemistry, device and therapeutic-use classifications.
Filing trend: a 2017 peak, then a multi-year pullback
Publications rose to 293 in 2017, the peak so far, then declined through the last complete year on record. The -52% move from 220 records in 2021 to 105 in 2024 is the clearest complete-year signal available; years after 2024 are still filling in as publications catch up to filing dates roughly 18 months behind.
Technology composition: medicinal and sterilising classes dominate
A61K (medicinal preparations) and A61L (sterilising and disinfecting) each cover roughly 40% of the 6,517 records, reflecting the field's split between active formulation and material sterility claims. A61B (diagnosis and surgery, 25.1%) and A61F (implants and prostheses, 13.6%) point to the device-integration side of the field, while C08L (polymer compositions, 4.8%) and C12N (microorganisms and genetic engineering, 9.3%) are comparatively thin — a sign that polymer-chemistry and biologic-production claims are less crowded than the formulation core.
Shares are the percentage of the 6,517 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Topical Hemostatic Agents with Eureka
This page is one run against one query. Ask Eureka your own question about topical hemostatic agents and every answer comes back with the patent numbers behind it.
Try EurekaA representative filing and the most-cited prior art
Resorbable oxidized cellulose embolization solution (US9782430B2)
A method for forming an embolism within a blood vessel is disclosed. The method includes implanting an oxidized cellulose embolization solution into a lumen of a blood vessel to form an embolism within the lumen. The oxidized cellulose is present in an amount from about 10% by weight to 20% by weight of the oxidized cellulose embolization solution. The method also includes adjusting recanalization time of the embolism, which may be adjusted by tailoring a degradation rate of the oxidized cellulose.Filed by Covidien, granted 2017-10-10 — illustrates how concentration-range and degradation-rate claims are used to fence off a specific formulation window within oxidized cellulose chemistry.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20120080336A1 | Staple cartridge comprising staples positioned within a compressible portion thereof | 2,433 |
| 2 | US20120080498A1 | Curved end effector for a stapling instrument | 2,398 |
| 3 | US20120248169A1 | Methods for forming tissue thickness compensator arrangements for surgical staplers | 2,161 |
| 4 | US5886026A | Anti-angiogenic compositions and methods of use | 2,018 |
| 5 | US20130256373A1 | Devices and methods for attaching tissue thickness compensating materials to surgical stapling instruments | 2,001 |
| 6 | US20130256380A1 | Layer of material for a surgical end effector | 1,928 |
| 7 | US8657176B2 | Tissue thickness compensator for a surgical stapler | 1,928 |
| 8 | US9386988B2 | Retainer assembly including a tissue thickness compensator | 1,918 |
| 9 | US5716981A | Anti-angiogenic compositions and methods of use | 1,909 |
| 10 | US20150297228A1 | Fastener cartridges including extensions having different configurations | 1,899 |
Citation counts reflect influence within this searched corpus and skew toward older, heavily-referenced filings — treat them as a map of foundational prior art, not a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the numbers
Three patterns stand out once the raw counts are set against each other: how top-heavy the assignee base is, what the post-2017 pullback actually means, and which IPC classes carry the real claim density.
A top-heavy field with room at the edges
The leading assignee alone holds 858 records, and the top 5 combined reach 2,680 — 41.1% of everything in scope. The top 10 extend that to 52.3%, meaning roughly half the field's output sits outside the ranked leaders entirely, spread across a long tail of single- or few-filing entities.
A cooling trend, not a collapsing one
Filings fell from 220 in 2021 to 105 in 2024, a -52% move over the only span that can currently be read as complete. The 2017 peak of 293 records has not been approached since. Years from 2025 onward are still filling in behind an approximate 18-month publication lag, so the apparent drop-off in the very latest year should not be read as the current filing rate.
Formulation and sterility claims dominate the class mix
A61K and A61L each cover roughly two in five records, confirming that most claim activity centers on medicinal-preparation chemistry and sterilisation processing rather than device mechanics. C08L polymer-composition claims sit at just 4.8% of records, a comparatively thin layer beneath the dominant chemistry classes.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to topical hemostatic agents, with the prior art for and against each one.
Who is filing, and where momentum is shifting
The ranked leaders in this dataset are dominated by surgical device and biopharma names with long-running hemostatic agent portfolios. Recent-year momentum, however, shows a pullback across several of the largest filers rather than fresh acceleration.
The single largest filer by a wide margin
The top-ranked assignee holds 858 records, more than three times the fifth-place total of 267. That gap is the clearest sign of first-mover advantage in this field's core formulation and device claims.
A steep drop after the leader
Fifth place sits at 267 records and tenth place at 88 — a fast decline that suggests the field's real competitive contest happens well below the top spot, among firms building narrower formulation or device-integration niches.
Recent-year activity is pulling back across the biggest names
Several of the most prolific historical filers show sharp year-over-year declines in the latest year — down 67% or, in one case, to zero filings. Co-assignee activity is also concentrated, with one pairing linked across 277 shared records, suggesting consolidation of R&D partnerships rather than new entrants driving volume.
| Assignee | Recent year | YoY |
|---|---|---|
| Bioverativ Therapeutics Inc | 4 | -67% |
| Cilag GmbH International | 1 | -67% |
| Angiotech Pharmaceuticals Inc | 0 | -100% |
| Ethicon Endo-Surgery Inc | 0 | — |
| Baxter International Inc | 0 | — |
| Baxter Healthcare SA | 0 | — |
| Omrix Biopharmaceuticals Ltd | 0 | — |
| Biogen MA Inc | 0 | — |
Where to take this next
The dataset points to a field where the core chemistry classes are crowded but adjacent branches remain open. Two directions make sense for teams deciding where to file or partner next.
Map claim boundaries before filing in A61K or A61L
With A61K and A61L each covering roughly 40% of records, a new filing in either class needs a tight freedom-to-operate check against the leading assignees' concentration-range and processing claims before committing R&D spend.
Run a freedom-to-operate check in Eureka →Explore the thinner polymer-composition layer
C08L claims cover only 4.8% of records, well below the formulation core. That gap is worth testing with a novelty search focused on polymer-carrier hemostat formulations rather than the crowded oxidized-cellulose or gelatin-matrix space.
Search white space in Eureka →Common questions about topical hemostatic agent patents
The dataset's assignee ranking shows one company holding 858 records, well ahead of the next-ranked filers. The top 5 assignees combined account for 2,680 records, or 41.1% of the 6,517 records in scope, and the top 10 extend that to 52.3%. That leaves roughly half the field's output distributed across a long tail of smaller filers, so a newcomer's competitive check should look well beyond the top names.
Filings peaked at 293 records in 2017 and have declined since, with the clearest complete-year signal being a -52% drop from 220 records in 2021 to 105 in 2024. Years after 2024 show lower counts still, but publication typically lags filing by around 18 months, so the most recent one to two years understate true activity rather than proving a further decline. Treat 2024 as the last reliable data point for trend reading.
A61K (medicinal preparations) and A61L (sterilising and disinfecting) each cover roughly 40% of the 6,517 records and represent the formulation and material-sterility core of the field. A61B (diagnosis and surgery, 25.1%) and A61F (implants and prostheses, 13.6%) capture the device-integration side, while C08L (polymer compositions, 4.8%) is comparatively thin. Because records can carry multiple IPC codes, these shares add up to more than 100% of the record total.
US9782430B2, assigned to Covidien, claims a method of implanting a resorbable oxidized cellulose embolization solution with the oxidized cellulose present at 10% to 20% by weight, with recanalization time tunable via degradation rate. It blocks formulations that fall within that specific concentration window and rely on the same degradation-rate mechanism for timing control. Formulations outside that weight range, or using a different mechanism to control resorption timing, are not necessarily covered, but any close variant needs a specific freedom-to-operate check against this claim language.
The thinnest layer in the technology composition is C08L polymer compositions at 4.8% of the 6,517 records, well below the roughly 40% coverage of the core A61K and A61L formulation classes. Swelling-ratio-controlled powder formulations and handling-property optimisation for powder delivery also show comparatively less claim density than the dominant oxidized-cellulose and gelatin-matrix chemistries. These are the sub-areas most worth a targeted novelty search before committing to a filing strategy in the crowded core classes.
Research Topical Hemostatic Agents in depth with Eureka
Go past this page: query the whole topical hemostatic agents corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.